NCT05336279View on ClinicalTrials.gov

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

May 27, 2022

Study Completion Date

June 20, 2022

Conditions
Solid Tumor
Interventions
DRUG

famitinib malate T(5 mg*4)、famitinib malate R(20 mg)

TR Group: famitinib malate T on day 1, famitinib malate R on day 13.

DRUG

famitinib malate T(5 mg*4)、famitinib malate R(20 mg)

RT Group: famitinib malate R on day 1, famitinib malate T on day 13.

Trial Locations (1)

230001

The First Affiliated Hospital of USTC, Jinan

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY